The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C07 | Beta blocking agents | |
| 3 | C07A | Beta blocking agents | |
| 4 | C07AA | Beta blocking agents, non-selective | |
| 5 | C07AA12 | Nadolol |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.16 g |
| Active Ingredient | Description | |
|---|---|---|
| Nadolol |
Nadolol is a synthetic nonselective beta-adrenergic receptor blocking agent. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CORGARD Tablet | FDA, National Drug Code (US) | MPI, US: SPL/Old |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
